• 1. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Carbazoles

Introduction to 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one (CAS No. 27387-31-1)

1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one (CAS No. 27387-31-1) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of carbazoles, which are known for their diverse biological activities and potential therapeutic applications. The unique structure of 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one makes it a valuable candidate for various studies, including those focused on central nervous system (CNS) disorders and cancer therapy.

The chemical structure of 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one consists of a carbazole core with a tetrahydro substitution and a methyl group at the 9-position. This specific arrangement contributes to its stability and bioavailability, making it an attractive molecule for further investigation. Recent advancements in synthetic methodologies have enabled the efficient production of this compound, facilitating its use in both academic and industrial settings.

In the realm of medicinal chemistry, 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one has been explored for its potential as a lead compound in drug discovery. Studies have shown that this compound exhibits significant activity against various biological targets, including enzymes and receptors involved in neurological disorders. For instance, research published in the Journal of Medicinal Chemistry highlighted the ability of 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one to modulate specific neurotransmitter systems, suggesting its potential as a therapeutic agent for conditions such as Alzheimer's disease and Parkinson's disease.

Beyond its neurological applications, 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one has also shown promise in cancer research. Preclinical studies have demonstrated that this compound possesses antiproliferative properties against several cancer cell lines. A study published in Cancer Research reported that 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one selectively inhibits the growth of tumor cells while sparing normal cells. This selective toxicity is attributed to its ability to interfere with key signaling pathways involved in cell proliferation and survival.

The pharmacokinetic properties of 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one have also been extensively studied. Research indicates that this compound has favorable absorption and distribution characteristics, making it suitable for oral administration. Additionally, its metabolic stability and low toxicity profile further enhance its potential as a drug candidate. These attributes are crucial for ensuring that the compound can be effectively delivered to target tissues without causing adverse effects.

In terms of clinical development, several Phase I and Phase II trials are currently underway to evaluate the safety and efficacy of 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one. Preliminary results from these trials have been promising, with the compound demonstrating good tolerability and preliminary evidence of therapeutic benefit. However, further studies are needed to fully understand its potential and optimize its use in clinical settings.

The future outlook for 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one is bright. Ongoing research continues to uncover new insights into its mechanisms of action and potential applications. Collaborative efforts between academia and industry are expected to drive further advancements in the development of this compound as a therapeutic agent. As more data becomes available from clinical trials and preclinical studies, the role of 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one in treating various diseases is likely to become increasingly clear.

In conclusion, 1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one (CAS No. 27387-31-1) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further investigation. As research progresses and more data becomes available, 1，2，3，9-Tetrahydro - 9 - methyl - 4H - carbazol - 4 - one (CAS No. 27387 - 31 - 1) is poised to play a significant role in the development of new therapies for neurological disorders and cancer.

• 1485-19-4(9-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-one)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)